Since p16INK4a expression is a marker of cellular senescence, combining ICIs with senescence-modulating therapies could be another therapeutic strategy in women with tumours exhibiting high p16INK4a expression and enhanced immune cell infiltration [84]. The gene discussed is CDKN2A; the disease is neoplasm.